<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161553">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02052895</url>
  </required_header>
  <id_info>
    <org_study_id>IVD2001</org_study_id>
    <nct_id>NCT02052895</nct_id>
  </id_info>
  <brief_title>Utility of Presepsin in Distinguishing Between Sepsis and SIRS</brief_title>
  <official_title>Utility of Presepsin in Distinguishing Between Sepsis and SIRS (Systemic Inflammatory Response Syndrome): an Exploratory, Prospective Observational Study in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mochida Pharmaceutical Company, Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to evaluate the diagnostic accuracy of presepsin levels to
      discriminate between sepsis and SIRS upon presentation with critical illness compatible with
      either sepsis or systemic inflammatory response syndrome (SIRS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Presepsin Concentration in Plasma</measure>
    <time_frame>Up to 30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the Receiver Operator Curve (ROC) curve of the plasma presepsin concentration for discriminating between SIRS and sepsis</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">226</enrollment>
  <condition>SIRS</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Sepsis/SIRS</arm_group_label>
    <description>Patients with sepsis or SIRS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients without SIRS, sepsis, or end stage renal disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End Stage Renal Disease</arm_group_label>
    <description>Patients with end stage renal disease, without SIRS or sepsis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma Blood serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with presentation to ICU with critical illness compatible with either sepsis or
        systemic inflammatory response syndrome (SIRS).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Sepsis/SIRS Patients

        Inclusion Criteria:

          -  Male or female aged ≥ 21 years

          -  Appropriate clinical data to enable classification into sepsis or SIRS

          -  Written informed consent by the patient or legally authorized representative

          -  Critical illness consistent with SIRS or sepsis, to be enrolled  within 18 hours of
             presentation

        Exclusion Criteria:

          -  No informed consent

          -  Unacceptable risk imposed by extra blood sampling, such as by gross hemorrhage with a
             hematocrit &lt; 20%

        Control

        Inclusion Criteria:

          -  Male or female aged ≥ 21 years

          -  Does not meet clinical criteria for sepsis or SIRS

          -  Written informed consent by the patient or legally authorized representative

        Exclusion Criteria:

          -  No informed consent

          -  Unacceptable risk imposed by extra blood sampling, such as by gross hemorrhage with a
             hematocrit &lt; 20%

        End Stage Renal Disease

        Inclusion Criteria:

          -  Male or female aged ≥ 21 years

          -  Documented diagnosis of end stage renal disease currently undergoing dialysis

          -  Does not meet clinical criteria for sepsis or SIRS

          -  Written informed consent by the patient or legally authorized representative

        Exclusion Criteria:

          -  No informed consent

          -  Unacceptable risk imposed by extra blood sampling, such as by gross hemorrhage with a
             hematocrit &lt; 20%
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Nasraway, MD, FCCM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patric Gibbons</last_name>
      <phone>617-636-0240</phone>
      <email>pgibbons1@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Stanley Nasraway, MD, FCCM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxiu Lei</last_name>
      <email>Yuxiu.Lei@Lahey.org</email>
    </contact>
    <investigator>
      <last_name>Jana Hudcova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 6, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presepsin</keyword>
  <keyword>Sepsis</keyword>
  <keyword>SIRS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
